

In the Sequence Listing

Please replace the Sequence Listing (pages 133-156) with the Substitute Sequence Listing (pages 1-20) submitted herewith. Please also enter the CRF form of the Sequence Listing submitted herewith.

Remarks

The Substitute Sequence Listing has been submitted to correct typographical errors in the sequence and numeric identifiers of SEQ ID NO:3. Specifically, SEQ ID NO:3 has been amended to delete the nucleotide "t" at position 1508. Additionally, the base pair total for SEQ ID NO:3 has been amended to recite "1525" where it previously recited "1526."

Support for the amendment to SEQ ID NO:3 can first be found, for example, in Figure 2D. The additional nucleotide "t" at position 1508 of SEQ ID NO:3 differs from the disclosure of Figure 2D, which does not have a nucleotide "T" at position 1508. Furthermore, SEQ ID NO:3, having 1526bp, and Figure 2D having 1525bp, differ in length by one nucleotide.

Additional support for the amendment to SEQ ID NO:3 can be found in the specification, for example, on page 84, lines 21 to 23. Here, the specification indicates that an antisense primer anneals with its 5' end at position 1259 bp of the truncated VEGF-2 cDNA, whereby the nucleotide sequence of the truncated VEGF-2 cDNA is shown in SEQ ID NO:3 (see figure legend of Figure 2A-D, page 6). The specification further indicates that the 1259 bp position is 266 bp before the last nucleotide of the cDNA. Thus, by adding these two figures the length of SEQ ID NO:3 is figured to be 1525 bp (i.e. 1259 +

266 = 1525). Therefore, one of skill in the art would deduce that Figure 2D has the correct length of 1525 bp and that the length in SEQ ID NO:3 is not correct.

Substitute drawings of Figures 1A-29 have been provided in accordance with 37 C.F.R. § 1.84(g).

The amendments are fully supported by the application and claims as originally filed. Thus, no new matter has been added by way of amendment. Entry of the above amendment is therefore respectfully solicited.


Conclusion

Applicants respectfully request that the above-made amendments and remarks be entered and made of record in the file history of the instant application. Applicants believe that this application is in condition for substantive examination. If in the opinion of the Examiner, a telephone conference would expedite prosecution, the undersigned can be reached at the telephone number indicated below.

If there are any fees due in connection with the filing of this paper, please charge the fees to Deposit Account No. 08-3425.

Respectfully submitted,

Dated: Jan 25, 2002


Michele M. Wales (Reg. No. 43,975)
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
Telephone: (301) 610-5772

Enclosures
MMW/AKR/lcc